BPC-157 and cancer: what the angiogenesis argument gets right and wrong
Last updated: October 2, 2026 · 5 min read · By the Grey Peptides Editorial Board
- The worry has a real basis: in lab and rat studies, BPC-157 helps grow new blood vessels through the VEGFR2 receptor, the same pathway many cancer drugs try to block.
- The step from there to "BPC-157 causes cancer" is untested. Searches of PubMed found no study that tested whether it makes tumours grow, and the developer group argues it controls blood-vessel growth rather than simply driving it.
- What decides the question is missing: only three small human pilot studies exist, none followed people for cancer, and FDA reviewers found the substance poorly characterised. Anyone with a cancer history should treat it as an unknown.
The argument in one paragraph
Tumours need blood vessels to grow beyond a small size, and many cancer drugs work by blocking the signals that build them, chiefly VEGF and its receptor VEGFR2. BPC-157 Low, a 15-amino-acid peptide sold widely online, is promoted for healing precisely because it encourages new blood vessels. So, the argument runs, a peptide that turns that signalling up could help a hidden tumour along. A 2025 literature and patent review by Józwiak and colleagues raised this possibility among its concerns about the peptide 1 2.
What the argument gets right
The mechanism is real, at least in the laboratory. In a 2017 study, BPC-157 increased blood-vessel density in the chick embryo membrane assay and in human endothelial-cell cultures, sped the return of blood flow to the ischaemic hind limbs of rats, and raised the expression of VEGFR2, but not of VEGF-A itself. It also caused VEGFR2 to be taken into the cell and switched on the VEGFR2-Akt-eNOS signalling pathway; blocking that uptake blocked the effect 3. A 2025 review of BPC-157 for muscle and tendon healing describes the same picture: the peptide acts through VEGFR2 and nitric-oxide signalling to promote blood-vessel growth, which is what makes it attractive for poorly supplied tissues such as tendons 4.
So the concern is not invented. A substance that strengthens the main pro-angiogenic receptor in endothelial cells is, in principle, the kind of substance an oncologist would want to know about.
What the argument cannot show
Plausibility is not evidence of harm. PubMed searches for BPC-157 with "tumor" and with "cancer", run on October 2, 2026, returned 13 and 7 records; none tested whether BPC-157 starts or accelerates tumours, and most came from the Zagreb group that developed it. The cancer concern is an inference from mechanism, not a finding.
The developer group disputes the inference directly. In a published comment on the Józwiak review, Sikiric and colleagues argue that BPC-157 controls angiogenesis rather than simply promoting it: in their cornea models it does not cause new vessels to grow into the cornea and instead opposes it, and they report anti-tumour effects in their own animal and cell studies 2. An earlier review co-written with the same group even proposed BPC-157 as a possible treatment for cancer cachexia, the muscle wasting of advanced cancer, on the strength of preclinical work 5. These are the claims of the peptide's developers in their own models, not independent confirmation; the Józwiak authors published a reply to the comment 6.
The literature also has quality problems of its own. The Józwiak review states that BPC-157 is not currently on WADA's banned list 1; the 2026 Prohibited List names it in section S0 7. A review that misstates a checkable fact is a reason to read its speculative claims carefully too.
What FDA reviewers found
When the FDA's compounding committee considered BPC-157 in July 2026, agency staff proposed not adding it to the list of substances pharmacies may compound. Their briefing document found it not well characterised physically and chemically, and found the information needed to assess the risk of immune reactions unavailable 8. The committee voted 8 to 6, with one abstention, to recommend it anyway 9; at our last check on September 25, 2026, the FDA had not acted on that vote 9. None of this is a cancer finding in either direction; it is a statement that the basic safety information is missing.
What nobody knows
Human data are minimal. The 2025 musculoskeletal review counted three small pilot studies in people, for knee pain, interstitial cystitis and intravenous safety and pharmacokinetics; none reported adverse effects, and none was designed or long enough to detect cancer 4. No study has followed people who use BPC-157 for tumour outcomes, and no study has given it to people with cancer under observation. Products sold online add a separate uncertainty about what is actually in the vial.
For someone with active cancer, a cancer history or a high inherited risk, the honest position is that BPC-157's effect on tumours is unknown, and that its known mechanism points in the direction that would matter if the effect turned out to be real. That is a conversation to have with an oncologist before, not after. Our wider guide to peptides and cancer covers the other peptides people ask about.
Frequently asked questions
Does BPC-157 cause cancer?
No study has shown that it does, and none has tested it properly. The concern comes from its mechanism: in lab and rat studies it promotes blood-vessel growth through VEGFR2, the pathway tumours use. Only three small human pilot studies exist, none designed to detect cancer.
Is BPC-157 safe for someone with a history of cancer?
Its effect on tumours is unknown. Because it promotes blood-vessel growth in laboratory models, people with active cancer or a cancer history should discuss it with their oncologist; there is no human evidence either way.
Does BPC-157 have anti-cancer effects?
Its developers report anti-tumour effects in their own animal and cell models and have proposed it for cancer cachexia, but these findings have not been independently confirmed or tested in people.
What did the FDA say about BPC-157's safety?
FDA staff found in June 2026 that BPC-157 is not well characterised and that the information needed to assess immune-reaction risk is unavailable. The compounding committee recommended it 8 to 6 in July; at our last check, the FDA had not acted.
Related on Grey Peptides
Sources
- Józwiak, M., et al. (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel), 18(2). PMID: 40005999 · doi:10.3390/ph18020185
- Sikiric, P., et al. (2025). BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185. Pharmaceuticals (Basel), 18(10). PMID: 41155565 · doi:10.3390/ph18101450
- Hsieh, M. J., et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl), 95(3), 323-333. PMID: 27847966 · doi:10.1007/s00109-016-1488-y
- McGuire, F. P., et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med, 18(12), 611-619. PMID: 40789979 · doi:10.1007/s12178-025-09990-7
- Kang, E. A., et al. (2018). BPC157 as Potential Agent Rescuing from Cancer Cachexia. Curr Pharm Des, 24(18), 1947-1956. PMID: 29898649 · doi:10.2174/1381612824666180614082950
- Józwiak, M., et al. (2025). Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on "Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185". Pharmaceuticals (Basel), 18(10). PMID: 41155566 · doi:10.3390/ph18101451
- World Anti-Doping Agency. Prohibited List 2026, section S0 (names BPC-157); read October 2, 2026. WADA
- US FDA. Briefing document: evaluation of BPC-157 (free base) and BPC-157 acetate for inclusion on the 503A bulk drug substances list, Pharmacy Compounding Advisory Committee, posted June 29, 2026; read October 2, 2026. FDA
- US FDA. Pharmacy Compounding Advisory Committee, July 23-24, 2026 meeting: votes; status as of September 25, 2026. FDA
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead